key: cord-0952016-j0hruwk0 authors: Sharma, P.; Basu, S.; Mishra, S.; Gupta, E.; Aggarwal, R.; KALE, P. R.; Mundeja, N.; Charan, B. S.; Singh, G. K.; Singh, M. M. title: SARS-CoV-2 seroprevalence in Delhi, India: September October 2021: a population based seroepidemiological study date: 2021-12-29 journal: nan DOI: 10.1101/2021.12.28.21268451 sha: 4f936ff099ec2d61f49d289a55aed1ed4116d4f9 doc_id: 952016 cord_uid: j0hruwk0 Background We conducted a repeat serosurvey in Delhi, India to estimate the seroprevalence of SARS-CoV-2 in the general population and compare the antibody prevalence in the vaccinated and non-vaccinated groups. Methods This cross sectional study was conducted from September 24 to October 14 2021 in 280 wards of Delhi among 27811 participants selected through a multistage sampling technique with housing settlement based stratification. The SARS-CoV-2 immunoglobulin (IgG) antibodies were screened with the VITROS (Ortho Clinical Diagnostics, Raritan, NJ, USA) assay (90% sensitivity, 100% specificity). Results A total of 24895 (89.5%) samples were seropositive. The crude seroprevalence was 87.99% (95% CI 89.1, 89.8), weighted for age and sex was 88% (95% CI 87.6, 88.4), and after adjustment of assay performance was estimated as 97.5% (95% CI 97.0, 98.0). The weighted seroprevalence in the 11 districts ranged from 84.9% (South-West district) to 90.8% (East district) Females in all the age-groups (<18, 18-49 and [≥]50) had significantly higher odds of seropositivity (p<0.001). On adjusted analysis, the odds of seroconversion in the participants vaccinated with at-least one dose of either Covid-19 vaccine (Covishield/Covaxin) was more than four times compared to the unvaccinated (aRR 4.2 (3.8, 4.6)). The seroprevalence was also comparable among the complete and partially vaccinated subgroups for both vaccines (Table 4). Most (86.8%) seropositive individuals had a SARS-CoV-2 signal/cut-off [≥]4.0 except in children Conclusions We observed IgG antibodies against SARS-CoV-2 in most of the general population of Delhi with likely higher antibody titers in the vaccinated compared to the unvaccinated groups. Delhi, the capital city-state of India, experienced a severe second wave of Covid-19, predominantly driven by the Delta variant during April-June 2021 [1, 2] . The city having a population of ~19 million, recorded ~1.43 million cases and 25090 deaths until October 21 2021 [3] . Covid-19 seroprevalence studies estimate the population level humoral immunity profile by direct measurement of SARS-CoV-2 antibodies induced through either natural infection or vaccination [4] . Repeated cross-sectional seroepidemiological studies when regionally localized enable seroprevalence monitoring for guiding infection prevention and control strategies by mounting effective public health interventions [5] . Serial serosurveys previously indicated that the age and sex weighted seroprevalence in Delhi in the ≥5 population increased from 24.71% (95% CI 24.01 to 25.42) in August-October 2020 to 50.52% (95% CI 49.94 to 51.10 in January 2021 [6, 7] . till date [8] . As of 21 st October 2021, 19.8 million cumulative vaccine doses were administered to the eligible beneficiaries [8] . We conducted this sixth round of Delhi state serosurvey to estimate the seroprevalence of SARS-CoV-2 in the general population and compare the antibody prevalence in the vaccinated and non-vaccinated groups. This was a cross-sectional, seroepidemiological study among individuals aged five and above who were recruited from 274 wards in the state of Delhi from September 24 to October 14 A total of 100 participants each were enrolled from all wards except the Delhi Cantonment and the New Delhi wards. The sample size of approximately 28,000 was estimated at 99% All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.28.21268451 doi: medRxiv preprint confidence level, 1% absolute precision, 56% expected prevalence from the previous serosurvey [7] , design effect of 1.5, and considering a non-response rate of 10%. The sampling was conducted within each ward based on the residential settlement types which included planned colonies, urban slums, resettlement colonies, unauthorized colonies, and rural areas [9] . Within each ward, the proportion of participants selected from each settlement type was stratified according to their tentatively estimated population size. The participants were selected for this household serosurvey through a multistage sampling technique having the following steps: (i). Sampling areas within each settlement type by simple random sampling (ii) Household selection by systematic random sampling, and (iii). Age-order procedure for selection of a single individual within each selected household. A trained phlebotomist or lab technician under aseptic precautions collected 3-4 mL of venous blood which were transported and processed at the designated laboratory. Anti-SARS-CoV-2 IgG antibodies were detected using chemiluminescent technology based VITROS® assay on VITROS® 3600 (Ortho Clinical Diagnostics, Raritan, NJ, USA) [10] . The assay has a documented sensitivity 90% and specificity of 100% which is deemed acceptable for SARS-CoV-2 seroprevalence surveys [11]. A customized android tablet application was used for electronic data collection by field volunteers recruited for this survey. The variables included sociodemographic data, past history of Covid-19 disease, and Covid-19 vaccination status. This questionnaire data was subsequently merged with the laboratory antibody test result data in Microsoft Excel 2013. The data were analysed using SPSS Version 25 (IBM Corp., Armonk, NY, USA). The seroprevalence estimates were weighted to match the state demographics by age and sex and reported as proportions with 95% confidence intervals (CIs). The adjusted seroprevalence was estimated through statistical correction of the weighted seroprevalence by incorporating the assay characteristics in the Rogan-Gladen estimator, where true (adjusted) prevalence = weighted prevalence + (specificity -1)/(specificity + sensitivity -1) [12] . Results were expressed as frequency and proportions for categorical variables and mean and standard deviation for continuous variables. The chi-square test was used to assess association between categorical variables. A binary logistic regression analysis was conducted by considering IgG antibody as the outcome and the following independent variables; sex: male/female, age: <18/≥18, settlement: planned/other, past-history of Covid-19: present/absent, and vaccination status: no dose/at-least one dose. A p-value of <0.05 was considered statistically significant. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in A total of 28491 laboratory samples were collected of which 27811 were successfully processed in the laboratories (Table 1) . A total of 24895 (89.5%) samples were seropositive. The crude seroprevalence was 87.99% (95% CI 89.1, 89.8). The seroprevalence weighted for age and sex was 88% (95% CI 87.6, 88.4). The weighted seroprevalence in the districts ranged from 84.9% (South-West district) to 90.8% (East district) ( Table 1 ). The adjusted seroprevalence, calculated after statistical correction the weighted seroprevalence for assay characteristics was 97.5% (95% CI 97.0, 98.0). On bivariate analysis, females in all the age-groups (<18, 18-49 and ≥50) had significantly higher odds of seropositivity (p<0.001) ( Table 2) . Our logistic regression model was statistically significant with Chi2 (5) Table 3) . The seroprevalence was also comparable among the complete and partially vaccinated subgroups for both vaccines ( Table 4 ). The signal/ cut off (S/CO) of SARS-CoV-2 IgG in the seropositive samples (n=24,895) ranged from 1.00 to 22.8 (median 11.40, IQR 6.97, 14.5). A total of 21620 (86.8%) seropositive individuals had a S/CO ≥4.0, signifying the presence of high antibody titres. The S/CO <4 was observed in 14.2% female seropositive participants compared to 12.4% male seropositive participants, and this difference was statistically significant (p<0.001). Furthermore, S/CO <4 was observed in 29.1% participants aged below 18 compared to 11.1% and 9.2% in the 18-49 and ≥50 age-group seropositive participants, respectively (p<0.001). The robust antibody response translated into effective population protection. From August 1 2021 to October 26 2021, the state on average daily recorded 39 new cases (range 0 to 151), and 0.44 deaths (range 0 to 5). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.28.21268451 doi: medRxiv preprint The findings of the sixth round of the serosurvey in Delhi indicate that nearly nine in ten individuals aged 5 years and above in Delhi had detectable IgG SARS-CoV-2 antibodies which on assay adjustment reflect near universal seropositivity. The seroprevalence in Delhi was higher compared to other Indian cities and states but comparable with Mumbai city (86.64%) probably because of the high severity of the second wave of the pandemic in these metropolitan cities ( Table 5 ). The weighted and adjusted seroprevalence of IgG SARS-CoV-2 antibodies in Delhi increased from 50.1% and 56.1% in January 2021 to 88.1% and 97%, respectively during September-October 2021 [7] . During the second wave of the countrywide Covid-19 pandemic, Delhi recorded nearly 0.737 million cases including 11075 deaths [2] . Consequently, like the national pattern, the increase in seroprevalence was due to both natural infection and vaccination [13] . However, during this nine-month period, the seroprevalence increased in unvaccinated adults from 50.3% to 82%, and in children aged five years and above from 52.4% to 81.7%, which is indicative of natural infection being the primary driver of immune response in a large proportion of the population. Similar to the trends in previous serosurvey rounds, the seroprevalence was higher in adults compared to children and adolescents, in those having past-history of Covid-19, and in residents of planned colonies in comparison to other settlements. The seropositivity was also significantly higher in females compared to males despite lower rates of vaccination in the former suggesting a biological rather than behavioural phenomenon [6, 7] . Previous studies suggest antibodies to SARS-CoV-2 persist at-least one year after natural infection conferring durable protection against reinfection or symptomatic disease [14] . Unlike a previous study, we found only a small difference in the rates of seroconversion between the Covishield and Covaxin vaccines [15] . Furthermore, the proportion of seronegative vaccinated individuals in our study was very low even in those who had received only one dose of either vaccine. High seroprevalence was observed even in DM patients despite the possible association with an immunocompromised condition. However, in comparison, the nationwide ICMR study reported 10-14% of the vaccinated individuals remained seronegative even after receiving two vaccine doses [13] . This is possible because of the comparatively higher burden of natural infection in Delhi throughout the pandemic and later during second wave, and the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Consequently, vaccination coverage needs acceleration in the unvaccinated and the partially vaccinated adults especially for protection against severe disease and death. The emergence of All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.28.21268451 doi: medRxiv preprint the Omicron variant of concern which has been reported to have the ability to bypass both natural and vaccine induced immunity has major ramifications for the public health surveillance and response systems [22] . Nevertheless, the presence of hybrid immunity in a majority of the adult population in Delhi and India may confer enhanced protection from symptomatic or severe disease in comparison to populations in whom vaccine induced immunity is predominant. Continuous genomic surveillance, pandemic preparedness, and adherence to non-pharmaceutical interventions without any laxity or complacence requires high and sustained prioritization to diminish morbidity and mortality from future waves of the pandemic. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 29, 2021. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.28.21268451 doi: medRxiv preprint Government of India. #IndiaFightsCorona COVID-19 Delhi reported more COVID cases, deaths in April-May than since beginning of pandemic Covid-19 dashboard. Available from: mohfw.gov.in (Accessed The power of antibody-based surveillance Interpreting SARS-CoV-2 seroprevalence studies for public health decision The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated populationbased seroepidemiological study Second Wave of the COVID-19 Pandemic in Delhi New Delhi: Ministry of Health and Family Welfare Categorisation of settlement in Delhi VITROS. 2021 Available from Estimating prevalence from the results of a screening test Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre,prospective cohort study (SIREN) Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted We thank all the district Nodal officers of Delhi for facilitating the data and sample collection. We express thanks to the ATE Chandra Foundation and ACT grants, and IDFC Foundation for technical support. We also thank Ms. Arti Kakkar for her assistance with data management for this investigation.